// App-Quantinova.ai

ABS113 : FEIBA GLOBAL OUTCOME (FEIBA GO) STUDY: REAL‐WORLD DATA IN PATIENTS WITH CONGENITAL HEMOPHILIA AND INHIBITORS

Researchers

Presenter

  • C. Hermans

Principal Investigators

  • C. Ngrier

  • P. A. Holme

  • C. Escuriola-Ettingshausen

  • A. R. Cid

  • K. Khair

  • J. Oldenburg

  • J. Botha

  • N. Kemenyash

  • M. Kokot-Kierepa

  • J. Windyga

Medical Centers

  • Saint-Luc University Hospital, Brussels, Belgium

  • Louis Pradel Cardiology Hospital, University Claude Bernard, Lyon, France

  • Department ofHaematology, Oslo University Hospital and Instituteof Clinical Medicine University of Oslo, Oslo,Norway

  • Haemophilie Zentrum Rhein Main, Morfelden-Walldorf, Germany

  • Unidad de Hemostasia y Trombosis, Hospital Universitario y Politecnico La Fe, Valencia, Spain

  • Centre for Outcomes and Experience Research in Children's Health, Illness and Disability (ORCHID), Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom

  • Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany

  • Takeda Pharmaceutical International AG, Zürich, Switzerland

  • Department of Disorders of Haemostasis andInternal Medicine, Institute of Haematology andTransfusion Medicine, Warsaw, Poland

Locations

  • Belgium

  • France

  • Norway

  • Germany

  • Spain

  • United Kingdom

  • Switzerland

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved